Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website
Combodart reduces prostate volume and, therefore, causes a decrease in serum PSA levels by approximately 50% after 6 months in patients with BPH. 1
Patients receiving Combodart should have a new PSA baseline established after 6 months of treatment. It is recommended to monitor PSA values regularly thereafter. 1
Any confirmed increase from lowest PSA level while on Combodart should be carefully evaluated as it may signal the presence of prostate cancer or non-compliance to therapy with Combodart. 1
Treatment with dutasteride does not interfere with the use of PSA as a tool to assist in the diagnosis of prostate cancer after a new baseline has been established.1
Additional checks on treatment compliance or other factors that can affect PSA values should be considered in the interpretation of results.1
Please refer to the SPC for full information on how to monitor PSA levels in patients receiving Combodart.
References:
- Combodart Prescribing Information available at www.medicines.ie, last accessed June 2020.
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
Combodart is registered trademark of the GlaxoSmithKline Group of companies
